Tarsus Pharmaceuticals Inc
NASDAQ:TARS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (12.1), the stock would be worth $-22.99 (135% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -34.7 | $65.97 |
0%
|
| Industry Average | 12.1 | $-22.99 |
-135%
|
| Country Average | 19.6 | $-37.31 |
-157%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$2.6B
|
/ |
Jan 2026
$-71m
|
= |
|
|
$2.6B
|
/ |
Dec 2026
$-28.7m
|
= |
|
|
$2.6B
|
/ |
Dec 2027
$172m
|
= |
|
|
$2.6B
|
/ |
Dec 2028
$324.9m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
|
2.8B USD | -34.7 | -42.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 30.4 | 42.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 21.7 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.2 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 23.3 | 29.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 12 | 15.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 16.1 | 20.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.7 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 10.3 | 20.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 8.8 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Tarsus Pharmaceuticals Inc
Glance View
Tarsus Pharmaceuticals Inc. emerged as a dynamic player in the biotech landscape, primarily driven by its innovative approach to addressing unmet medical needs in ocular health. The company gained attention for its work on developing therapeutic solutions for conditions with significant market potential but limited existing treatments. With a focused approach on tackling Demodex blepharitis, an inflammation of the eyelids caused by a common parasitic mite, Tarsus developed TP-03, an innovative product spearheading its advancement in ocular therapeutics. This biopharmaceutical firm's strategy revolves around capitalizing on its scientific expertise to create niche products that cater to specific, underserved segments, aiming for leadership in targeted therapeutic areas. Tarsus Pharmaceuticals relies on the successful commercialization of its treatments to generate revenue, which primarily comes from sales and partnerships. By shepherding its products through clinical trials and securing regulatory approvals, Tarsus positions itself competitively in the pharmaceutical market. Its business model is centered on developing specialized treatments that fill gaps overlooked by larger pharmaceutical companies, allowing it to carve out a unique space in the industry. Furthermore, by building strategic alliances and leveraging partnerships, Tarsus enhances its capabilities for broader distribution and market penetration, thus ensuring sustainable growth and fostering innovation in therapeutic solutions.
